View Older Stories View More Recent Stories

Nov 9, 2023 08:05AM Agile Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
Oct 26, 2023 08:05AM Agile Therapeutics to Report Third Quarter 2023 Financial Results and Provide Business Update on Thursday, November 9, 2023
Oct 4, 2023 04:30PM Agile Therapeutics Reports an Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
Sep 5, 2023 08:05AM Agile Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 9, 2023 08:05AM Agile Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
Jul 26, 2023 08:30AM Agile Therapeutics to Report Second Quarter 2023 Financial Results and Provide Business Plan Updates on Wednesday, August 9, 2023
Jun 26, 2023 08:01AM Agile Therapeutics Announces the Availability of Twirla® to MMCAP Infuse Members
Jun 15, 2023 04:05PM Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
Jun 15, 2023 04:05PM Agile Therapeutics Announces the Availability of Twirla® through FPA Women’s Health
Jun 13, 2023 04:06PM Agile Therapeutics (AGRX) Announces New Agreement with vitaCare Prescription Services to Improve Access to Twirla
Jun 13, 2023 04:05PM Agile Therapeutics Announces New Agreement with vitaCare® Prescription Services to Improve Access to Twirla®
May 25, 2023 04:05PM Agile Therapeutics Announces Closing of $7.5 Million Public Offering
May 23, 2023 05:47AM Agile Therapeutics (AGRX) Prices 1.87M Share Offering at $3.96/sh
May 22, 2023 08:00PM Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
May 22, 2023 08:00PM Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
May 11, 2023 04:05PM Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
May 8, 2023 08:00AM Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
Apr 28, 2023 08:05AM Agile Therapeutics (AGRX) Reports Prelim Q1 Results
Apr 28, 2023 08:01AM Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
Apr 28, 2023 08:01AM Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
Apr 26, 2023 09:02AM Agile Therapeutics (AGRX) Regains Compliance With Nasdaq Minimum Bid Price Requirement
Apr 26, 2023 09:01AM Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Apr 26, 2023 09:01AM Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
Mar 22, 2023 04:05PM Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
Mar 22, 2023 04:05PM Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
Mar 21, 2023 09:05AM Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
Mar 21, 2023 09:05AM Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
Feb 27, 2023 08:31AM Agile Therapeutics (AGRX) Granted 180-Day Extension by Nasdaq to Regain Compliance
Feb 27, 2023 08:31AM Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
Feb 27, 2023 08:31AM Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
Feb 1, 2023 08:01AM Agile Therapeutics (AGRX) Provides Clinical Update on Twirla and Status of Pipeline Evaluation
Feb 1, 2023 08:01AM Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
Feb 1, 2023 08:01AM Agile Therapeutics Provides Clinical Update on Twirla and Status of Pipeline Evaluation
Jan 26, 2023 04:30PM Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
Jan 26, 2023 04:30PM Agile Therapeutics Announces Distribution of Series C Preferred Stock to its Holders of Common Stock
Jan 9, 2023 07:00AM Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
Jan 9, 2023 07:00AM Agile Therapeutics Provides Updates on 2022 Twirla Performance and 2023 Commercial Plan
Dec 1, 2022 08:30AM Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
Dec 1, 2022 08:30AM Agile Therapeutics To Present At The Upcoming RHK Capital Disruptive Growth Conference
Nov 7, 2022 04:05PM Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Nov 7, 2022 04:05PM Agile Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Oct 26, 2022 08:30AM Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
Oct 26, 2022 08:30AM Agile Therapeutics to Report Third Quarter 2022 Financial Results and Provide Business Update on Monday, November 7, 2022
Oct 7, 2022 04:25PM Agile Therapeutics Announces Reorganization of Leadership Team
Oct 7, 2022 04:25PM Agile Therapeutics Announces Reorganization of Leadership Team
Aug 11, 2022 04:05PM Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Aug 11, 2022 04:05PM Agile Therapeutics Reports Second Quarter 2022 Financial Results and Provides Corporate Update
Jul 6, 2022 05:16PM Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
Jul 6, 2022 05:16PM Agile Therapeutics Announces Closing of $24 Million Upsized Public Offering
Jul 1, 2022 09:21AM Agile Therapeutics (AGRX) Prices 26.67M Share and Warrant Offering at $0.90/sh
View More Recent Stories View Older Stories